Health-Care Heroes Finalist

CardioMEMS Founder Dr. Jay Yadav Chosen as Health-Care Heroes Finalist by Atlanta Business Chronicle

Winners to be announced at Awards Dinner on May 19 at the Cobb Energy Centre

ATLANTA, May 5, 2011 /PRNewswire/ — CardioMEMS, Inc., an Atlanta-based medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced that its founder and CEO Jay Yadav, M.D., has been chosen as a finalist for the Atlanta Business Chronicle Health-Care Heroes Awards. The awards are presented by the Atlanta Business Chronicle to honor the people and organizations that demonstrate excellence and deserve recognition in the health-care community, from the doctors finding cures for deadly diseases to organizations serving Atlanta’s health-care needs.

Dr. Yadav was nominated for the award in the Health Care Innovation category for his development of the Champion Heart Failure Monitoring System, the first permanently implantable, wireless, battery-free device that provides cardiac catheterization-type data from home for patients suffering from chronic heart failure.  In 2010, CardioMEMS completed its clinical trial for its Champion System, demonstrating a 38% reduction in heart failure related hospitalizations.  In February, the positive Champion trial results were published in The Lancet, one of the world’s leading medical journals.

The Health-Care Heroes Award winners will be revealed at the 14th annual award presentation dinner on May 19 at the Cobb Energy Centre.

About CardioMEMS, Inc.

CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The company’s technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure, and hypertension. CardioMEMS miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data, which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency (RF) energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient’s physician. CardioMEMS developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient’s quality of life and delivering more efficient and cost effective health care. More information about CardioMEMS is located at www.cardiomems.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc. Champion is a trademark of CardioMEMS, Inc.

Caution: The CardioMEMS’ heart failure pressure measurement system is an investigational device limited by federal law to investigational use.

©2011 PR Newswire. All Rights Reserved.

 

Hello Friends

Dear Friends

I wanted to share with you the settlement of my dispute with the Cleveland Clinic. Below is the text of the Joint Statement issued by myself and the Cleveland Clinic:

“Cleveland Clinic and Dr. Jay Yadav agree on the need for integrity in scientific research and the disclosure of potential conflicts of interest by those conducting scientific research, and a process for administering conflict of interest policies. Cleveland Clinic acknowledges that Dr. Yadav did disclose an interest in the sale of Angioguard Inc. to Cordis Inc. while conducting research sponsored by Cordis. Cleveland Clinic commissioned an independent review, which concluded that the integrity of Dr. Yadav’s research regarding Angioguard/Cordis was not compromised by his financial relationships with Angioguard/Cordis. Cleveland Clinic recognizes Dr. Yadav’s valuable contributions to cardiology during his tenure at Cleveland Clinic, and Cleveland Clinic and Dr. Yadav wish each other continuing success.”

Marshalla and I are very pleased to put this behind us and deeply appreciate the support we have gotten from so many friends and colleagues over the past three and a half years.

Please find below some links to news reports.

» The Heart :
Cleveland Clinic settles suit with Jay Yadav stemming from 2006 “nonrenewal” over implied COI nondisclosure

In a jointly released statement, the Cleveland Clinic acknowledges that Yadav did in fact disclose an interest in the sale of Angioguard and that his research at the clinic was not compromised by his financial relationships.    (Continue reading)

» MedCity News :
Cleveland Clinic settles lawsuit, admits Jay Yadav kept policy

The Cleveland Clinic has admitted that its former staff physician and inventor, Dr. Jay Yadav, did not run afoul of the health system’s conflicts of interest policy as it had claimed in 2006 while declining to renew Yadav’s employment contract.    (Continue reading)

– Jay